Ostarine

Ostarine (Enobosarm) emerged from research efforts aimed at creating safer alternatives to anabolic steroids, with a patent filed in 2001. Company GTx Inc developed it and partnered with Merck in 2007, although their collaboration ended in 2010. Selective action on androgen receptors in muscle and bone allows it to enhance lean muscle mass without causing significant androgenic side effects. It has gained traction in bodybuilding for losing fat and maintaining muscle during cutting cycles. Medically Ostarine has undergone multiple trials for muscle wasting diseases, including cancer-related conditions.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.